| Q4 2022 |
3 |
$29.9M |
|
|
|
GRAB, NU, PTCT |
13F-HR |
2/3/2023, 11:09 AM |
| Q3 2022 |
3 |
$27M |
|
|
|
GRAB, NU, PTCT |
13F-HR |
11/4/2022, 10:02 AM |
| Q2 2022 |
3 |
$24.8M |
|
|
|
GRAB, NU, PTCT |
13F-HR |
8/5/2022, 09:50 AM |
| Q1 2022 |
4 |
$40.2M |
+$17.7M |
|
+$17.7M |
GRAB, NU, PTCT, NEWT |
13F-HR |
5/6/2022, 08:23 AM |
| Q4 2021 |
2 |
$45.6M |
+$45.2M |
|
+$45.2M |
GRAB, PTCT |
13F-HR |
2/4/2022, 08:44 AM |
| Q3 2021 |
1 |
$304K |
|
|
|
PTCT |
13F-HR |
11/8/2021, 02:16 PM |
| Q2 2021 |
3 |
$28.2M |
+$238K |
-$6M |
-$5.77M |
DCT, PTCT, NEWT |
13F-HR |
8/5/2021, 02:29 PM |
| Q1 2021 |
2 |
$35.3M |
|
-$66.4M |
-$66.4M |
DCT, PTCT |
13F-HR |
5/5/2021, 10:02 AM |
| Q4 2020 |
3 |
$107M |
+$102M |
|
+$102M |
DCT, SNY, PTCT |
13F-HR |
2/5/2021, 03:36 PM |
| Q3 2020 |
3 |
$5.12M |
|
-$22.4M |
-$22.4M |
SNY, PHR, PTCT |
13F-HR |
10/30/2020, 01:41 PM |
| Q2 2020 |
4 |
$28.1M |
+$4.44M |
|
+$4.44M |
SNY, PHR, PTCT, NEWT |
13F-HR |
8/11/2020, 11:03 AM |
| Q1 2020 |
3 |
$20.3M |
+$3.41K |
|
+$3.41K |
SNY, PTCT, NEWT |
13F-HR |
4/30/2020, 09:33 AM |
| Q4 2019 |
3 |
$23.4M |
+$4.6K |
|
+$4.6K |
SNY, PTCT, NEWT |
13F-HR |
2/14/2020, 10:00 AM |
| Q3 2019 |
3 |
$21.5M |
+$3.5K |
|
+$3.5K |
SNY, NEWT, PTCT |
13F-HR |
11/6/2019, 10:58 AM |
| Q2 2019 |
3 |
$20.2M |
|
-$8.5K |
-$8.5K |
SNY, NEWT, PTCT |
13F-HR |
8/7/2019, 10:25 AM |
| Q1 2019 |
12 |
$149M |
+$10.6K |
|
+$10.6K |
MRK, SNY, BP, PFE, GSKXXXX, TTE |
13F-HR |
4/30/2019, 11:40 AM |
| Q4 2018 |
13 |
$138M |
+$3.01K |
|
+$3.01K |
MRK, SNY, PFE, TTE, GSKXXXX, BP |
13F-HR |
2/8/2019, 09:07 AM |
| Q3 2018 |
14 |
$151M |
+$3.27K |
-$862K |
-$859K |
MRK, SNY, TTE, BP, PFE, GSKXXXX |
13F-HR |
10/31/2018, 11:51 AM |
| Q2 2018 |
21 |
$238M |
+$1.42M |
|
+$1.42M |
MS, JPM, ADM, BP, MRK, TTE |
13F-HR |
7/27/2018, 10:17 AM |
| Q1 2018 |
20 |
$230M |
+$224K |
|
+$224K |
MS, JPM, ADM, SNY, AZN, TTE |
13F-HR |
5/1/2018, 02:25 PM |
| Q4 2017 |
19 |
$230M |
+$6.42K |
|
+$6.42K |
MS, JPM, SNY, ADM, AZN, MRK |
13F-HR |
1/26/2018, 01:08 PM |
| Q3 2017 |
20 |
$229M |
|
-$269 |
-$269 |
MS, SNY, MRK, ADM, JPM, AZN |
13F-HR |
10/27/2017, 10:18 AM |
| Q2 2017 |
21 |
$235M |
+$4.74K |
|
+$4.74K |
MS, SNY, MRK, ADM, JPM, GSKXXXX |
13F-HR |
7/28/2017, 10:28 AM |
| Q1 2017 |
21 |
$232M |
+$987 |
|
+$987 |
MS, ADM, SNY, MRK, JPM, GSKXXXX |
13F-HR |
5/4/2017, 08:30 AM |
| Q4 2016 |
25 |
$228M |
+$1.02M |
-$470 |
+$1.02M |
MS, ADM, SNY, MRK, JPM, GSKXXXX |
13F-HR |
2/14/2017, 01:48 PM |
| Q3 2016 |
24 |
$221M |
+$1.81M |
-$16.2M |
-$14.4M |
ADM, MRK, GSKXXXX, SNY, AZN, MS |
13F-HR |
11/14/2016, 04:49 PM |
| Q2 2016 |
26 |
$231M |
+$2.74M |
-$470 |
+$2.74M |
ADM, SNY, GSKXXXX, MRK, AZN, TTE |
13F-HR |
8/12/2016, 11:28 AM |
| Q1 2016 |
36 |
$367M |
|
|
|
SNY, BAC, C, AAL, ADM, GSKXXXX |
13F-HR |
5/13/2016, 10:35 AM |